Barclays’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $215K | Sell |
4,553
-15,046
| -77% | -$710K | ﹤0.01% | 3483 |
|
|
2025
Q1 | $766K | Buy |
19,599
+14,953
| +322% | +$584K | ﹤0.01% | 2600 |
|
|
2024
Q4 | $252K | Sell |
4,646
-995
| -18% | -$54K | ﹤0.01% | 3411 |
|
|
2024
Q3 | $283K | Buy |
5,641
+5,229
| +1,269% | +$262K | ﹤0.01% | 3312 |
|
|
2024
Q2 | $18K | Sell |
412
-3,367
| -89% | -$147K | ﹤0.01% | 3912 |
|
|
2024
Q1 | $190K | Sell |
3,779
-2,335
| -38% | -$117K | ﹤0.01% | 3362 |
|
|
2023
Q4 | $369K | Buy |
6,114
+2,802
| +85% | +$169K | ﹤0.01% | 3174 |
|
|
2023
Q3 | $189K | Buy |
+3,312
| New | +$189K | ﹤0.01% | 3060 |
|
|
2023
Q1 | – | Sell |
-55,952
| Closed | -$587K | – | 4370 |
|
|
2022
Q4 | $587K | Buy |
55,952
+40,768
| +268% | +$428K | ﹤0.01% | 2496 |
|
|
2022
Q3 | $118K | Buy |
15,184
+101
| +0.7% | +$785 | ﹤0.01% | 3350 |
|
|
2022
Q2 | $79K | Buy |
+15,083
| New | +$79K | ﹤0.01% | 3560 |
|